• 1. Department of Hematology, Nanfang Hospital of Southern Medical University, Guangzhou, 510515, P.R.China;
  • 2. Nursing Department, Nanfang Hospital of Southern Medical University, Guangzhou, 510515, P.R.China;
  • 3. Nanfang Nursing Centre for Evidence-based Practice: A Joanna Briggs Institute Affiliated Group, Guangzhou, 510515, P.R.China;
ZHAO Jie, Email: 1113722345@qq.com
Export PDF Favorites Scan Get Citation

Objectives To systematically review the efficacy and safety of palifermin on oral mucositis (OM) and acute graft versus host disease (aGVHD) for hematological malignancy patients undergoing hematopoietic stem cell transplantation (HSCT).Methods PubMed, The Cochrane Library, Web of Science, EMbase, Clinicaltrials.gov, CNKI and WanFang Data databases were electronically searched to collect randomized controlled trials (RCTs) of the efficacy of palifermin on OM and aGVHD for hematological malignancy patients undergoing HSCT from inception to September 30th, 2018. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies, then, meta-analysis was performed by using RevMan 5.3 software.Results A total of 7 RCTs involving 904 patients were included. The results of meta-analysis showed that: palifermin could reduce the duration of OM grade 2 to 4 (MD=−4.21, 95%CI −7.83 to −0.58, P=0.02), OM grade 3 to 4 (MD=−2.54, 95%CI −4.61 to −0.46, P=0.02) significantly for hematological malignancy patients undergoing HSCT. However, no significant difference was found in the prevalence of aGVHD grade 2 to 4 (RR=1.29, 95%CI 0.95 to 1.75, P=0.11), aGVHD grade 3 to 4 (RR=0.99, 95%CI 0.55 to 1.77, P=0.97), OM grade 2 to 4 (RR=0.86, 95%CI 0.72 to 1.03, P=0.11) and OM grade 3 to 4 (RR=0.82, 95%CI 0.65 to 1.03, P=0.08) between palifermin group and placebo group. The prevalence of paresthesia (RR=4.24, 95%CI 1.24 to 14.56, P=0.02) and erythema (RR=1.49, 95%CI 1.06 to 2.09, P=0.02) were significantly higher in palifermin group.Conclusions The durations of OM grade 2 to 4, 3 to 4 are significantly reduce in patients receiving palifermin compared with those receiving a placebo, however, no statistically significant difference are found in the incidence of aGVHD grade 2 to 4, 3 to 4, OM grade 2 to 4, 3 to 4. Parethesia and erythema are more prevalent among patients using palifermin. Therefore, advantages and disadvantages of palifermin should be considered when used in clinical.

Citation: LIU Ying, ZHOU Chunlan, ZHAO Jie, OU Jiexia. Efficacy of palifermin on oral mucositis and aGVHD for hematological malignancy patients undergoing hematopoietic stem cell transplantation: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2019, 19(4): 439-447. doi: 10.7507/1672-2531.201812096 Copy

  • Previous Article

    Efficacy and safety of hydroxychloroquine or chloroquine for oral lichen planus:a meta-analysis
  • Next Article

    Efficacy and safety of the combination of dezocine and sufentanil versus sufentanil for postoperative analgesia: a meta-analysis